| Identification | Back Directory | [Name]
CV-6209 | [CAS]
100488-87-7 | [Synonyms]
Cv 6209 chloride
2-(2-Acetyl-6-methoxy-3,9-dioxo-4,8-dioxa-2,10-diazaoctacos-1-yl)-1-ethyl- pyridinium Chloride
2-(N-Acetyl-N-(2-methoxy-3-octadecylcarbamoyloxypropoxycarbonyl)aminomethyl)-1-ethylpyridinium
Pyridinium, 2-(2-acetyl-6-methoxy-3,9-dioxo-4,8-dioxa-2,10-diazaoctacos-1-yl)-1-ethyl-, chloride | [Molecular Formula]
C34H60ClN3O6 | [MOL File]
100488-87-7.mol |
| Chemical Properties | Back Directory | [Appearance]
Pale-Yelow Solid | [storage temp. ]
Store at -20°C | [solubility ]
Water: 10 mg/ml | [form ]
A crystalline solid | [color ]
Off-white to light yellow | [Stability:]
Store at -200C. |
| Hazard Information | Back Directory | [Chemical Properties]
Pale-Yelow Solid | [Uses]
Competitive PAF receptor antagonist. Inhibits PAF induced human platelet aggregation. Inhibits PAF induced hypotension and lethality. | [Description]
CV-6209 is a potent antagonist of the platelet-activating factor (PAF) receptor, inhibiting aggregation of rabbit and human platelets induced by PAF with IC50 values of 75 and 170 nM, respectively. It has little action on platelet aggregation induced by arachidonic acid, ADP, or collagen. CV-6209 is bioavailable, as it prevents PAF-induced hypotension in rats, while not blocking hypotension triggered by arachidonic acid , histamine, bradykinin , or isoproterenol . CV-6209 is used to study the role of PAF receptor signaling in vitro and in vivo. | [in vivo]
CV-6209 (i.v.) inhibits PAF (0.3 μg/kg; i.v.)-induced hypotension in rats (ED50=0.009 mg/kg) with no effect on the hypotension induced by arachidonic acid, histamine, bradykinin and isoproterenol[1].
CV-6209 (66 μg; i.v.) reduces asparaginase-induced hypersensitivity compared with nonpretreated, sensitized mice[3]. | [References]
[1] Z TERASHITA. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.[J]. Journal of Pharmacology and Experimental Therapeutics, 1987, 242 1: 263-268.
[2] H. S. LEONG. Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor[J]. Journal of Leukocyte Biology, 2007, 83 2: 263-271. DOI: 10.1189/jlb.0607339
[3] SILVIA MUSIO. Anaphylaxis to a self-peptide in the absence of mast cells or histamine[J]. Laboratory Investigation, 2009, 89 4: 398-405. DOI: 10.1038/labinvest.2009.4 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|